917796
NanoFabTx™ PEG-PLGA drug formulation screening kit
for synthesis of PEGylated nanoparticles
Synonym(s):
NanoFabTx reagent kit, PEG-PLGA nanoparticles
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12161503
NACRES:
NA.23
Recommended Products
description
Drug loading screening kit, for synthesis of PEGylated PLGA nanoparticles
Kit components :
PEGPLGA-50L(912808-500mg)
PEGPLGA-75L(913049-500mg)
PEGPLGA-50H (915955-500mg)
PEGPLGA-75H (915718-500mg)
Stabilizer-Nano (907766-5g)
Quality Level
application(s)
advanced drug delivery
storage temp.
2-8°C
General description
NanoFabTx™ PEG-PLGA drug loading screening kit is a ready-to-use nanoformulation kit for the synthesis of PEGylated PLGA nanoparticles 50 nm to 350 nm in size. This kit provides properly selected PEGylated PLGAs, stabilizer, and formulation protocols for synthesis by nanoprecipitation and microfluidic methods. Four different PEGylated PLGAs are included in this kit, allowing rapid screening of optimal materials for enhancing drug loading. Protocols for two different particle synthesis methods are included.
- A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
- A Microfluidics protocol using commercial platforms or syringe pumps.
Application
NanoFabTx™ nanoformulation reagent kits enable users to encapsulate a wide variety of therapeutic drug molecules in PEGylated PLGA nanocarriers for targeted or sustained drug delivery without the need for lengthy trial-and-error optimization. PEGylated PLGAs are well suited towards applications involving sustained release because PEGylation has been shown to improve the circulation half-life of polymeric nanocarriers by altering the solubility and shielding the nanocarrier from enzymes and antibodies that may induce degradation, secretion, and clearance. Because poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable polymer approved by the FDA for biomedical and pharmaceutical applications, PLGA-based nanoparticles synthesized with the NanoFabTx™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.
Features and Benefits
- Requires minimal laboratory setup
- Optimized protocols with step-by-step instructions for either nanoprecipitation or microfluidics-based synthesis
- Yields specifically sized, low polydispersity biodegradable, PEGylated PLGA nanoparticles from 50 nm to 350 nm in size
- Maximizes the encapsulation of hydrophobic drugs
- Four different PEGylated PLGAs are included
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
related product
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Y Li et al.
Journal of controlled release : official journal of the Controlled Release Society, 71(2), 203-211 (2001-03-29)
The aim of the present work was to assess the merits of PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles as protein and peptide drugs (PPD) carriers. PEG-PLGA copolymer, which could be used to prepare the stealth nanoparticles or long-circulating nanoparticles, was synthesized
Hassan A Almoustafa et al.
International journal of pharmaceutics, 533(1), 275-284 (2017-09-26)
Nanoprecipitation is a simple and increasingly trending method for nanoparticles preparation. The self-assembly feature of poly (ethylene glycol)-poly (lactide-co-glycolic acid) (PEG-PLGA) amphiphilic copolymer into a nanoparticle and its versatile structure makes nanoprecipitation one of the best methods for its preparation.
Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system.
Locatelli E, et al
Journal of Nanoparticle Research, 14, 1316-1316 (2012)
FDA-approved poly(ethylene glycol)−protein conjugate drugs.
Polym. Chem., 2, 1442-1448 (2011)
Susanne Schöttler et al.
Nature nanotechnology, 11(4), 372-377 (2016-02-16)
The current gold standard to reduce non-specific cellular uptake of drug delivery vehicles is by covalent attachment of poly(ethylene glycol) (PEG). It is thought that PEG can reduce protein adsorption and thereby confer a stealth effect. Here, we show that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service